{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.2","upperLimit":"98.9","value":"97.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects were males with advanced prostate carcinoma. They were injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects were followed until day 336.\n\nLeuprolide Mesylate: Subcutaneous injection of 50mg Leuprolide Mesylate","id":"OG000","title":"Leuprolide Mesylate 50mg"}],"paramType":"MEAN","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"baseline to 28 days, 28 days to 336 days","title":"Efficacy of Leuprolide Mesylate (LMIS 50mg)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}